Table 2.
SARS-CoV-2 vaccination, infection, and treatment characteristics of the participants.
| Characteristic | <4-month cohort | 4–12-month cohort | p-valuec | Overall |
|---|---|---|---|---|
| No. of patients | 76 | 99 | 175 | |
| Donor Vaccination Status Pre-donation - no. (%) | <0.01 | |||
| No | 2 (3) | 20 (20) | 22 (13) | |
| Yes | 6 (8) | 1 (1) | 7 (4) | |
| Unknown/Not reported | 68 (89) | 78 (79) | 146 (83) | |
| SARS-CoV-2 infection - no. (%) | 0.82 | |||
| No infection | 62 (82) | 84 (85) | 146 (83) | |
| Prior to baseline | 9 (12) | 9 (9) | 0.58 | 18 (10) |
| Before HCT | 3 (4) | 1 (1) | 4 (2) | |
| After HCT | 0 (0) | 1 (1) | 1 (1) | |
| Date Unknown | 6 (8) | 7 (7) | 13 (7) | |
| After initiating vaccination | 5 (7) | 6 (6) | 11 (6) | |
| Participant vaccinated prior to HCT - no. (%) | 0.01 | |||
| No | 58 (76) | 90 (91) | 148 (85) | |
| Yes | 18 (24) | 9 (9) | 1.00 | 27 (15) |
| Ad26.COV2.S | 1 (1) | 1 (1) | 2 (1) | |
| mRNA-1273 | 8 (11) | 3 (3) | 11 (6) | |
| BNT16b2 | 8 (11) | 4 (4) | 12 (7) | |
| Unknown/Not reported | 1 (1) | 1 (1) | 2 (1) | |
| Anti-Nucleocapsid IgG - no. (%) | 0.45 | |||
| Negative | 66 (87) | 88 (89) | 154 (88) | |
| Positive | 10 (13) | 9 (9) | 19 (11) | |
| Unknown/Not reported | 0 (0) | 2 (2) | 2 (1) | |
| Received Vaccine dose 1 - no. (%) | ||||
| No | 0 (0) | 0 (0) | 0 (0) | |
| Yes | 76 (100) | 99 (100) | 0.72 | 175 (100) |
| Ad26.COV2.S | 1 (1) | 0 (0) | 1 (1) | |
| mRNA-1273 | 21 (28) | 28 (28) | 49 (28) | |
| BNT16b2 | 54 (71) | 71 (72) | 125 (71) | |
| Time from HCT to vaccine dose 1, month - median (range) | 3.4 (2.2–3.9) | 5.8 (4.0–11.8) | <0.01 | 4.2 (2.2–11.8) |
| Received Vaccine dose 2 - no. (%) | 1.00 | |||
| No | 3 (4) | 4 (4) | 7 (4) | |
| Yes | 73 (96) | 95 (96) | 0.86 | 168 (96) |
| mRNA-1273 | 21 (28) | 26 (26) | 47 (27) | |
| BNT16b2 | 52 (68) | 69 (70) | 121 (69) | |
| Time from HCT to vaccine dose 2, month - median (range) | 4.2 (2.9–5.1) | 6.7 (4.7–13.4) | <0.01 | 5.0 (2.9–13.4) |
| Time between vaccine dose 1 and 2, month - median (range) | 0.79 (0.5–1.79) | 0.75 (0.54–9.86) | 0.79 | 0.75 (0.5–9.86) |
| Received Vaccine dose 3 - no. (%) | 0.47 | |||
| No | 15 (20) | 25 (24) | 40 (23) | |
| Yes | 61 (80) | 74 (76) | 0.11 | 135 (77) |
| mRNA-1273 | 19 (25) | 14 (14) | 33 (19) | |
| BNT16b2 | 42 (55) | 60 (61) | 102 (58) | |
| Time from HCT to vaccine dose 3, month - median (range) | 6.1 (4.9–11.6) | 9.1 (5.8–17.9) | <0.01 | 7.6 (4.9–17.9) |
| Time between vaccine dose 2 and 3, month - median (range) | 1.6 (0.9–7.4) | 2.1 (0.9–6.8) | 0.29 | 1.9 (0.9–7.4) |
| Received Vaccine dose 4 - no. (%) | 1.00 | |||
| No | 72 (95) | 93 (94) | 165 (94) | |
| Yes | 4 (5) | 6 (6) | 1.00 | 10 (6) |
| mRNA-1273 | 1 (1) | 1 (1) | 2 (1) | |
| BNT16b2 | 3 (4) | 5 (5) | 8 (5) | |
| Time from HCT to vaccine dose 4, month - median (range) | 9.8 (9.1–10.2) | 12.2 (8.8–14.0) | 0.12 | 11.1 (8.8–14.0) |
| Time between vaccine dose 3 and 4, month - median (range) | 4.1 (3.6–6.5) | 4.7 (1.8–5.3) | 0.91 | 4.4 (1.8–6.5) |
| Receipt of tixagevimab-cilgavimab (Evusheld)a - no. (%) | ||||
| Pre-V1 | 0 (0) | 1 (1) | 1.00 | 1 (1) |
| Post-V1 | 0 (0) | 0 (0) | 0 (0) | |
| Post-V2 | 3 (4) | 2 (2) | 0.65 | 5 (3) |
| Post-V3 | 2 (3) | 2 (2) | 1.00 | 4 (2) |
| End-of-study | 18 (24) | 16 (16) | 0.25 | 34 (19) |
| Receipt of IVIGb - no. (%) | ||||
| Pre-V1 | 7 (9) | 2 (2) | 0.04 | 9 (5) |
| Post-V1 | 2 (3) | 3 (3) | 1.00 | 5 (3) |
| Post-V2 | 1 (1) | 3 (3) | 0.63 | 4 (2) |
| Post-V3 | 2 (3) | 3 (3) | 1.00 | 5 (3) |
| End-of-study | 4 (5) | 4 (4) | 0.73 | 8 (5) |
Percentages may not total 100 because of rounding. HCT indicates hematopoietic cell transplant; IVIG, intravenous immunoglobulin.
a
Within 6 months prior to sample collection.
b
Within 1 month prior to sample collection.
c
Calculated by a Fisher exact test or Kruskal–Wallis test as appropriate.